XPC rs2228001: Understanding the Lys939Gln Genetic Variant
The rs2228001 variant is a common genetic change in the XPC gene, which plays a vital role in repairing damaged DNA. Researchers have studied this variant to see if it influences how individuals respond to certain platinum-based chemotherapy treatments or their susceptibility to specific cancers.
What each genotype means
Typical DNA repair capacity
This genotype represents the ancestral or wild-type sequence for the XPC gene at this position. Research suggests this version of the gene is associated with standard DNA repair function, though individual response to platinum-based chemotherapy can be influenced by many other genetic and environmental factors. Please discuss any concerns regarding medication response or treatment planning with your clinician or pharmacist.
This is the most common genotype in many global populations, though it is less frequent than the C allele in some groups.
Altered DNA repair potential
Carrying one copy of the C allele may influence the efficiency of the nucleotide excision repair pathway. Some studies have observed associations between this genotype and variations in cancer susceptibility or chemotherapy response, but the evidence remains limited and inconsistent across different ancestries. You should consult with your healthcare provider to interpret this result in the context of your overall health and treatment plan.
This heterozygous genotype is frequently observed, reflecting the high prevalence of the C allele in European and South Asian populations.
Modified DNA repair potential
This genotype results in the Lys939Gln substitution, which has been studied for its potential to modulate DNA repair capacity. While some research indicates a correlation with altered risk for certain cancers or modified responses to platinum-based therapies, these findings are not definitive and vary significantly by population. Always discuss your specific clinical situation and any potential medication adjustments with your doctor or pharmacist.
This genotype is common, as the C allele frequency reaches approximately 0.38 in Europeans and 0.45 in South Asian populations.
What is the rs2228001 Variant?
The rs2228001 variant is a single nucleotide polymorphism (SNP) located within the XPC gene on chromosome 3. In genetics, a SNP represents a variation at a single position in the DNA sequence. Specifically, this variant involves a change where the nucleotide adenine (A) is replaced by cytosine (C). This change results in a missense mutation, meaning it alters the protein's amino acid sequence from lysine (Lys) to glutamine (Gln) at position 939. Because this change occurs in a gene responsible for maintaining genomic integrity, scientists have long been interested in whether this alteration affects the efficiency of cellular repair mechanisms. It is important to note that while this variant is widely studied, it is considered a common genetic feature rather than a rare mutation, and its presence does not inherently indicate a health condition.
The Role of the XPC Gene
The XPC gene provides instructions for making a protein that is a critical component of the nucleotide excision repair (NER) pathway. This pathway is the body's primary defense mechanism for identifying and fixing DNA damage caused by environmental factors, such as ultraviolet radiation or certain chemical exposures. When DNA is damaged, the XPC protein acts as a sensor, initiating the repair process to prevent mutations from accumulating. Because the NER pathway is essential for genomic stability, any variation that potentially alters the function of the XPC protein is of significant interest to researchers. By studying how variants like rs2228001 might influence the efficiency of this repair system, scientists hope to better understand how individual genetic differences contribute to variations in cancer risk and how cells handle damage from external stressors.
Research on Chemotherapy and Cancer Risk
Research into rs2228001 has primarily focused on its potential impact on platinum-based chemotherapy response and cancer susceptibility. Some studies have hypothesized that because the variant may influence DNA repair capacity, it could affect how well a patient responds to drugs like cisplatin, which work by damaging cancer cell DNA. However, the evidence remains mixed and limited. While some early reports suggested associations with chemotherapy outcomes or increased risk for certain cancers like lung or colorectal cancer, other large-scale meta-analyses have found no significant overall association. Because these findings are often inconsistent across different populations and study designs, the clinical utility of this variant for predicting treatment response is not currently established. If you are undergoing treatment, it is essential to discuss your specific medical situation and any concerns about medication response directly with your oncologist or pharmacist.
Understanding Your Results
It is important to approach genetic information about rs2228001 with a clear understanding of its limitations. Genetic variants are only one piece of a very complex puzzle that includes environmental factors, lifestyle, and other genetic markers. Because the scientific evidence regarding this variant is not definitive, it cannot be used to reliably predict how an individual will respond to medication or their personal risk of developing cancer. You should never make changes to your medical treatment or health decisions based on this information alone. If you have received results regarding this variant, consider them as a starting point for a conversation with a healthcare professional. They can provide context based on your full medical history and help you understand what, if any, relevance this information has for your personal health management.
How common is this variant?
The rs2228001 variant is common, with a minor allele frequency of approximately 0.38 in European populations and 0.45 in South Asian populations.
Frequently asked questions
Is rs2228001 a diagnostic test for cancer?
No, rs2228001 is not a diagnostic test for cancer. It is a common genetic variant that has been studied for potential associations with cancer risk, but it is not used by clinicians to diagnose or screen for the disease.
Does my genotype for rs2228001 determine my chemotherapy success?
Current research on this variant and chemotherapy response is inconsistent and limited. It is not a reliable predictor of how an individual will respond to treatment, and you should rely on your clinical team's expertise for treatment planning.
What should I do if I have the C/C genotype?
The C/C genotype is a common variation and does not require specific medical action. You should continue to follow standard health screenings and discuss any concerns about your genetic results with your doctor.
Where can I find more information about XPC?
You can find reliable information about the XPC gene and its function through resources like MedlinePlus Genetics or the National Center for Biotechnology Information (NCBI) Gene database.
Sources & further reading
Educational information only, last refreshed 10/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2228001?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29